Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models.
在临床前模型中，与司美格鲁肽相比，替拉帕肽引起的食欲减退和体重减轻伴随的胃肠道不良事件较少
期刊:Science Advances
影响因子:12.5
doi:10.1126/sciadv.adu1589
Borner Tito, Pataro Allison M, Doebley Sarah A, Furst Charles D, White Alex D, Gao Serena X, Chow Angela, Sanchez-Navarro Marcos J, Ghidewon Misgana Y, Halas Julia G, Mohiby Allaha Z, Willard Francis S, Grill Harvey J, Ai Minrong, Samms Ricardo J, Hayes Matthew R, De Jonghe Bart C
